Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Biol Sex Differ ; 13(1): 19, 2022 05 03.
Article in English | MEDLINE | ID: mdl-35505436

ABSTRACT

Sex and age associated differences in the tumor immune microenvironment of non-muscle invasive bladder (NMIBC) cancer and associated clinical outcomes are emerging indicators of treatment outcomes. The incidence of urothelial carcinoma of the bladder is four times higher in males than females; however, females tend to present with a more aggressive disease, a poorer response to immunotherapy and suffer worse clinical outcomes. Recent findings have demonstrated sex differences in the tumor immune microenvironment of non-muscle invasive and muscle invasive bladder cancer and associated clinical outcomes. However, a significant gap in knowledge remains with respect to the current pre-clinical modeling approaches to more precisely recapitulate these differences towards improved therapeutic design. Given the similarities in mucosal immune physiology between humans and mice, we evaluated the sex and age-related immune alterations in healthy murine bladders. Bulk-RNA sequencing and multiplex immunofluorescence-based spatial immune profiling of healthy murine bladders from male and female mice of age groups spanning young to old showed a highly altered immune landscape that exhibited sex and age associated differences, particularly in the context of B cell mediated responses. Spatial profiling of healthy bladders, using markers specific to macrophages, T cells, B cells, activated dendritic cells, high endothelial venules, myeloid cells and the PD-L1 immune checkpoint showed sex and age associated differences. Bladders from healthy older female mice also showed a higher presence of tertiary lymphoid structures (TLSs) compared to both young female and male equivalents. Spatial immune profiling of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) carcinogen exposed male and female bladders from young and old mice revealed a similar frequency of TLS formation, sex differences in the bladder immune microenvironment and, age associated differences in latency of tumor induction. These findings support the incorporation of sex and age as factors in pre-clinical modeling of bladder cancer and will potentially advance the field of immunotherapeutic drug development to improve clinical outcomes.


Subject(s)
Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Aging , Animals , Butylhydroxybutylnitrosamine/adverse effects , Carcinogens , Female , Humans , Male , Mice , Sex Characteristics , Tumor Microenvironment , Urinary Bladder/pathology , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/pathology
2.
Regul Toxicol Pharmacol ; 103: 166-173, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30685222

ABSTRACT

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is indicated to improve glycaemic control in adults of type 2 diabetes. In nonclinical studies, dapagliflozin was neither genotoxic nor carcinogenic. However, in some clinical studies, an increased incidence of bladder cancer was observed in the dapagliflozin group vs. the placebo. Therefore, this study was undertaken to determine if dapagliflozin can act as a promoter in a 2-stage bladder cancer model in rats induced with N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN). Rats given BBN (100 or 400 mg/kg, po) twice weekly for 6 weeks in Phase 1 were assigned in Phase 2 to receive daily dose of vehicle, dapagliflozin (0.5 mg/kg, po) or uracil (positive control, 3% in diet) from weeks 8-34. All bladders were evaluated by histopathology. Verifying the validity of the model, uracil increased the incidence of bladder cancer, while dapagliflozin had no effect on the incidence or invasiveness of transitional cell carcinoma. The exposure of dapagliflozin at 0.5 mg/kg/day in rats was 7 times the clinical exposure at maximal therapeutic dose (10 mg). In conclusion, dapagliflozin does not act as promoter or progressor of bladder cancer in a validated bladder cancer model in rats.


Subject(s)
Benzhydryl Compounds/administration & dosage , Disease Models, Animal , Glucosides/administration & dosage , Urinary Bladder Neoplasms/chemically induced , Administration, Oral , Animals , Benzhydryl Compounds/adverse effects , Butylhydroxybutylnitrosamine/administration & dosage , Butylhydroxybutylnitrosamine/adverse effects , Dose-Response Relationship, Drug , Glucosides/adverse effects , Male , Rats , Rats, Sprague-Dawley
3.
Methods Mol Biol ; 1655: 155-167, 2018.
Article in English | MEDLINE | ID: mdl-28889385

ABSTRACT

Urinary bladder cancer (UBC) is a common and complex malignancy, with a multifactorial etiology, like environmental factors, such as cigarette smoking, occupational exposure, and genetic factors.UBC exhibits considerable genotypic and phenotypic heterogeneity. Among all UBC lesions, urothelial carcinoma is the most frequently observed histological type. Despite all the developments made in urologic oncology field, therapeutic options remain inadequate. There is urgency for the identification and development of new antineoplastic drugs to replace or improve current protocols and in vivo models have been proven to be essential for this step. There are different animal models of UBC: Spontaneous and experimentally induced models (genetically engineered, transplantable-xenograft and syngeneic animals- and chemically induced models). N-butyl-N(4-hydroxybutil)nitrosamine (BBN) is the most suitable reagent to generate chemically induced in vivo models of UBC and to study bladder carcinogenesis. BBN has proven, over the years, to be very realistic and reliable. It is bladder specific, and induces high tumor incidence.


Subject(s)
Butylhydroxybutylnitrosamine/adverse effects , Carcinogens , Cell Transformation, Neoplastic/chemically induced , Disease Models, Animal , Urinary Bladder Neoplasms/pathology , Animals , Cell Transformation, Neoplastic/genetics , FANFT/adverse effects , Humans , Mice , Mice, Transgenic , Urinary Bladder Neoplasms/etiology , Urinary Bladder Neoplasms/therapy
4.
PLoS One ; 12(4): e0175494, 2017.
Article in English | MEDLINE | ID: mdl-28406993

ABSTRACT

Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progression and recurrence of non-muscle invasive bladder cancer (NMIBC). Although the immunoreaction elicited by BCG treatment is well documented, those induced by intravesical treatment with chemotherapeutic agents are much less known. We investigated the immunological profiles caused by mitomycin C, gemcitabine, adriamycin and docetaxel in the N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced orthotopic bladder cancer mouse model. Ninety mice bearing orthotopic bladder cancer induced by BBN were randomly divided into six groups and treated with chemotherapeutic agents once a week for four weeks. After last treatment, bladder and serum samples were analyzed for cell surface and immunological markers (CD4, CD8, CD56, CD204, Foxp3, and PD-L1) using immunohistochemistry staining. Serum and urine cytokine levels were evaluated by ELISA. All chemotherapeutic agents presented anti-tumor properties similar to those of BCG. These included changes in immune cells that resulted in fewer M2 macrophages and regulatory T cells around tumors. This result was compatible with those in human samples. Intravesical chemotherapy also induced systemic changes in cytokines, especially urinary interleukin (IL)-17A and granulocyte colony stimulating factor (G-CSF), as well as in the distribution of blood neutrophils, lymphocytes, and monocytes. Our findings suggest that intravesical treatment with mitomycin C and adriamycin suppresses protumoral immunity while enhancing anti-tumor immunity, possibly through the action of specific cytokines. A better understanding of the immunoreaction induced by chemotherapeutic agents can lead to improved outcomes and fewer side effects in intravesical chemotherapy against NMIBC.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Butylhydroxybutylnitrosamine/adverse effects , Cytokines/metabolism , Urinary Bladder Neoplasms/drug therapy , Adjuvants, Immunologic/pharmacology , Administration, Intravesical , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacology , Doxorubicin/administration & dosage , Doxorubicin/pharmacology , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Mitomycin/administration & dosage , Mitomycin/pharmacology , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/immunology , Treatment Outcome , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/immunology , Gemcitabine
5.
Microscopy (Oxf) ; 66(3): 198-203, 2017 Jun 01.
Article in English | MEDLINE | ID: mdl-28339760

ABSTRACT

Angiogenesis is essential for tumor growth, and an enhanced vasculature supplying nutrients and oxygen might reflect malignant potential. L-type amino acid transporter 1 (LAT1/4F2hc) comprises a major nutrient transport system responsible for the Na+-independent transport of large neutral amino acids. Seventy five to seventy eight percent N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinoma cells showed high LAT1/4F2hc expression. While the intracarcinoma microvasculatures of fenestrated endothelial cells highly expressing LAT1/4F2hc might progressively transport essential amino acids from the microvasculatures to the extracellular matrix, non-fenestrated endothelial cells and pericytes did not. The present study revealed that the tumor angiogenesis is one of target anti-L-type amino acid transporter 1 drug.


Subject(s)
Butylhydroxybutylnitrosamine/adverse effects , Fusion Regulatory Protein 1, Heavy Chain/ultrastructure , Large Neutral Amino Acid-Transporter 1/chemistry , Microvessels/ultrastructure , Urinary Bladder Neoplasms/blood supply , Urinary Bladder Neoplasms/ultrastructure , Animals , Immunohistochemistry/methods , Large Neutral Amino Acid-Transporter 1/ultrastructure , Male , Microscopy, Electron , Rats , Rats, Wistar , Urinary Bladder Neoplasms/chemically induced
6.
Pathol Oncol Res ; 22(4): 747-54, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27091758

ABSTRACT

Bladder cancer has been shown to resist programmed cell death with altered expression of both pro-apoptotic and anti-apoptotic proteins. To study is to investigate the apoptotic properties of Diindolylmethane (DIM) and Lupeol on N-Butyl-N-(4-hydroxybutyl) Nitrosamine (BBN) initiated and Dimethylarsinic Acid (DMA) promoted urinary bladder cancer. Sixty male Wistar rats were divided into 6 groups. Group I: Control. Group II: Rats were experimentally developed bladder carcinogenesis with BBN and DMA. Group III and IV: DIM and lupeol were administered after BBN treatment for 28 weeks. Group V and VI: DIM and lupeol alone treatment for 36 weeks. All the experimental rats were maintained and euthanized after 36 weeks protocol. Urinary bladder tissues were collected and processed for further investigations. Apoptotis and cell proliferative marker such as Bax, Bcl-2, caspase-3, caspase-9 and PCNA were quantified using immunohistochemical analysis. The Immunohistochemical expression of Bax, Bcl-2, caspase-3, caspase-9 and PCNA were aberrant in BBN + DMA treated tumor group. Administration of DIM and lupeol inhibited the progression of bladder cancer, induced the expression of apoptotic Bax, caspase-3, caspase-9 and inhibited the expression of anti-apoptotic Bcl-2, PCNA in the urinary bladder of rats. Administration of diindolylmethane and lupeol treatment induces apoptosis and cellular proliferation by its anti-carcinogenic properties. From our results DIM and lupeol would be the agent or adjunct for the treatment of bladder carcinogenesis.


Subject(s)
Apoptosis/drug effects , Butylhydroxybutylnitrosamine/adverse effects , Cacodylic Acid/adverse effects , Cell Proliferation/drug effects , Indoles/pharmacology , Pentacyclic Triterpenes/pharmacology , Urinary Bladder Neoplasms/drug therapy , Animals , Carcinogenesis , Carcinogens/administration & dosage , Caspase 3/metabolism , Caspase 9/metabolism , Male , Proliferating Cell Nuclear Antigen/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Rats, Wistar , Urinary Bladder/drug effects , Urinary Bladder/metabolism , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/metabolism , bcl-2-Associated X Protein/metabolism
7.
Oncol Rep ; 25(5): 1389-97, 2011 May.
Article in English | MEDLINE | ID: mdl-21369704

ABSTRACT

The effects of the EGFr inhibitor Iressa on development of urinary bladder cancers induced by hydroxybutyl(butyl)nitrosamine (OH-BBN) in rats were examined. Iressa treatment (4.5 or 1.5 mg/kg BW/day) beginning one week after the last dose of OH-BBN decreased the occurrence of large (>200 mg) bladder cancers at termination of the study by 75 and 52%, respectively. Treatment with Iressa (10 mg/kg BW/day) beginning one week or three months (delayed initiation) after the last dose of OH-BBN also significantly increased tumor latency and decreased the incidence of palpable bladder cancers. In the delayed initiation study, microscopic cancers already existed when treatment was initiated; implying that the effects of Iressa occur late in tumor progression. Potential pharmacodynamics and/or efficacy biomarkers modulated by short-term exposure (5 day) to Iressa (10 mg/kg BW/day) were determined in palpable bladder lesions by using three different approaches: i) direct immunohistochemical examination of EGFr related proteins; which showed that phosphorylated EGFr, AKT and ERK were significantly decreased; ii) measurement of protein expression by two dimensional gel electrophoresis and tandem mass spectrometry. This showed that the Annexin A2, MAP kinase kinase and nucleolin (all proteins associated with the VEGF pathway) were decreased in treated tumors; and iii) measurement of gene expression determined in gene microarrays demonstrated that numerous pathways were markedly altered by Iressa treatment. In particular, cell cycle genes related to the anaphase protein complex (APC) pathway, including CDC 20, cyclin B1, BUB1 and both of the Aurora kinases, were significantly decreased.


Subject(s)
Antineoplastic Agents/pharmacology , Biomarkers/metabolism , Butylhydroxybutylnitrosamine/adverse effects , ErbB Receptors/antagonists & inhibitors , Gene Expression Regulation, Neoplastic/drug effects , Quinazolines/pharmacology , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/drug therapy , Animals , Antineoplastic Agents/therapeutic use , Cluster Analysis , Female , Gefitinib , Gene Expression Profiling , Models, Biological , Quinazolines/therapeutic use , Rats , Signal Transduction/drug effects , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/prevention & control
8.
J Biochem ; 147(3): 353-60, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19880377

ABSTRACT

Down-regulation of carcinogen detoxifying enzymes might be a critical factor in tumour formation by increasing the carcinogen concentration in the target organ. Previous reports revealed that the expression of UGT1A mRNA is either lost or decreased in certain human cancer tissues, including urinary bladder cancer. To elucidate this down-regulation mechanism, we used an N-nitrosobutyl (4-hydroxybutyl) amine (BBN)-induced mouse urinary bladder carcinogenesis model. Similar to human cancer, the expressions of Ugt1a6, Ugt1a9 and total Ugt1a mRNA in the BBN-induced bladder cancer were markedly decreased compared with those of normal mice. BBN down-regulated the basal Ugt1a mRNA expression in a time-dependent manner and this was reversible in the first 2 weeks of BBN treatment. However, after 4 weeks of BBN treatment the repression became persistent after the cessation of BBN treatment. Aryl hydrocarbon receptor (AhR) regulates the constitutive and inducible expression of Ugt1a mRNA. We found that the constitutive Ugt1a mRNA expression is decreased in the bladder of AhR knockout (KO) mice. Furthermore, BBN-induced Ugt1a down-regulation was lost in AhR KO mice, and the canonical AhR target gene Cyp1a1 was similarly down-regulated by BBN in the bladder. These results demonstrate that BBN repressed Ugt1a mRNA expression via suppression of AhR signaling pathway during BBN-induced carcinogenesis.


Subject(s)
Butylhydroxybutylnitrosamine/adverse effects , Glucuronosyltransferase/metabolism , Receptors, Aryl Hydrocarbon/metabolism , Urinary Bladder Neoplasms/metabolism , Animals , Butylhydroxybutylnitrosamine/administration & dosage , Cytochrome P-450 CYP1A1/genetics , Cytochrome P-450 CYP1A1/metabolism , Down-Regulation , Gene Expression Regulation, Neoplastic/drug effects , Glucuronosyltransferase/genetics , Humans , Mice , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Signal Transduction , Time Factors , UDP-Glucuronosyltransferase 1A9 , Urinary Bladder Neoplasms/chemically induced
9.
Int J Urol ; 10(3): 160-6, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12622713

ABSTRACT

BACKGROUND: Recently, the anticarcinogenic effects of green tea have been studied in sites other than the urinary tract. Although the incidence of bladder cancer has increased, responses to therapy have been limited. The present work examined the preventive effects of green tea against bladder tumors induced in rats by the carcinogen, N-butyl-N-(4-hydroxybutyl)-nitrosamine(BBN). METHODS: From week 5 to week 9, all the groups were exposed to 0.05% BBN in the drinking water for 5 weeks. Rats were divided into four groups. Group 1 was fed a CE-2 diet and tap water for the entire experimental period and served as the control group. Group 2 was fed the green tea leaves after carcinogen exposure. Groups 3 and 4 received green tea leaves before carcinogen exposure. All rats were killed and examined at 44 weeks. RESULTS: Green tea leaves prevented the growth of BBN-induced urinary bladder tumors when given before the carcinogen. CONCLUSION: Green tea may inhibit tumor initiation in the bladder.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Butylhydroxybutylnitrosamine/adverse effects , Phytotherapy , Plant Preparations/therapeutic use , Tea , Urinary Bladder Neoplasms/prevention & control , Animals , Camellia sinensis , Catechin/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Male , Plant Leaves , Rats , Rats, Wistar , Treatment Outcome , Urinary Bladder Neoplasms/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...